Ribavirin lozenges
Function and Efficacy
1 Pharmacology Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of many viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. 2 Toxicological animal experiments have found that this product can induce benign tumors of the breast, pancreas, pituitary and adrenal glands, but its carcinogenicity to humans has not been confirmed. The drug can cause malformations of the head, palate, eyes, jaw, bones and gastrointestinal tract in animals such as hamsters, and reduce the survival of offspring, but primate experiments have not found any effect of the drug on the fetus. Cardiac damage occurred in mice, rats, and monkeys given oral ribavirin at doses of 30, 36, and 120 mg/kg or more for 4 weeks (equivalent to human doses of 4.8, 12.3, and 111.4 mg/kg for a 5 kg child or 2.5, 5.1, and 40 mg/kg for a 60 kg adult).
Ingredients
The main ingredient of this product is: Ribavirin.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| RibavirinIngredients |
Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. More |
36791-04-5 | 33 |
Appearance
This product is a capsule, and the contents are white powder.
Indication
Antiviral drug. Used to treat influenza and stomatitis.
Usage and Dosage
Oral administration. 1 Viral respiratory tract infection: Adults take 1.5 tablets at a time, 3 times a day, for a course of 7 days. 2 Skin rash virus infection: Adults take 3 tablets at a time, 3 times a day, for a course of 7 days. 3 Children take 10 mg/kg per day, divided into 4 doses, for a course of 7 days. The oral dosage for children under 6 years old is not determined
Adverse Reactions
Common adverse reactions include anemia and fatigue, which disappear after stopping the drug. Less common adverse reactions include fatigue, headache, insomnia, loss of appetite, nausea, vomiting, mild diarrhea, constipation, etc., and can cause a decrease in red blood cells, white blood cells and hemoglobin.
Precautions
This product is contraindicated for those who are allergic to it and pregnant women. 1. This product has a strong teratogenic effect. A daily dose of 1 mg/kg in rabbits can cause embryo damage, so it is contraindicated for pregnant women and women who may become pregnant (this product is eliminated very slowly in the body and cannot be completely eliminated from the body 4 weeks after stopping the drug). 2. A small amount of the drug is excreted through breast milk and is toxic to both mother and offspring. Therefore, breastfeeding women need to stop breastfeeding during the medication period and the breast milk should also be discarded. Since respiratory syncytial virus infection in breastfeeding women is self-limiting, this product is not used in such cases. 3. It is not recommended for the elderly.
Special Population Medication
Precautions for children: The oral dose for children under 6 years old has not been determined. Precautions for pregnancy and lactation: 1. This product has a strong teratogenic effect. A daily dose of 1 mg/kg in rabbits can cause embryo damage, so it is forbidden to be used in pregnant women and women who may become pregnant (this product is eliminated very slowly in the body and cannot be completely eliminated from the body 4 weeks after stopping the drug). 2. A small amount of the drug is excreted through breast milk and is toxic to both mother and offspring. Therefore, breastfeeding women should stop breastfeeding during the medication period and the breast milk should also be discarded. Since respiratory syncytial virus infection in lactating women is self-limiting, this product is not used in such cases. Precautions for the elderly: It is not recommended for the elderly.
Drug Interactions
This product has an antagonistic effect when used together with zidovudine, because this product can inhibit the conversion of zidovudine into active zidovudine phosphate.
Storage
Keep away from light and store in sealed container.
Packaging Specification
50mg
Validity Period
36 months
Manufacturer
Shandong Luyin Pharmaceutical Co., Ltd.
-
Founded in:
2007-08-16 -
Address:
Shandong Linyi High-tech Industrial Development Zone -
Tax NO.:
91371300727570960U -
Registered Funds:
65 million yuan -
Website:
-
Email: